Soluble TREM2 Mediates Blood Brain Barrier Permeability through Astrocyte Reactivity
This study demonstrates that soluble TREM2 (sTREM2) compromises blood-brain barrier integrity by inducing an inflammatory, reactive state in astrocytes that upregulates MMP2 secretion, leading to the degradation of tight junction proteins and increased permeability.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The brain is protected by a highly selective border known as the blood-brain barrier. This barrier acts as a gatekeeper, allowing essential nutrients to enter while keeping harmful substances and infections out. It is not a solid wall but a living structure made of tiny blood vessels lined with cells that seal themselves tightly together. To maintain this seal, these cells rely on special proteins that function like mortar between bricks. Surrounding these vessels are star-shaped support cells called astrocytes. These cells do not just provide structural support; they actively communicate with the blood vessels to ensure the barrier remains strong and functional. When the brain faces injury or disease, these astrocytes can change their behavior, becoming "reactive." While this reaction is often an attempt to heal, it can sometimes disrupt the delicate balance of the barrier, leading to leakage and further damage. Understanding exactly what triggers these changes is crucial for treating conditions where the brain's protection fails.
Researchers at the Albert Einstein College of Medicine and the Feinstein Institute for Medical Research have uncovered a new piece of this puzzle involving a protein called soluble TREM2. TREM2 is a molecule found on the surface of immune cells in the brain, helping them manage waste and maintain health. Sometimes, this protein is cut off from the cell surface and released into the fluid surrounding the brain, becoming "soluble." High levels of this soluble form are found in people with neurocognitive disorders, but scientists have not known exactly how it contributes to disease. The team set out to see if this floating protein could directly affect the blood-brain barrier by changing the behavior of the astrocytes that guard it.
To investigate this, the researchers created a model of the human blood-brain barrier in a laboratory dish. They grew human blood vessel cells on one side of a porous membrane and human astrocytes on the other, mimicking how these cells interact in the body. They then added soluble TREM2 to the side containing the astrocytes. The results showed that the protein did indeed change the astrocytes. Within hours, the astrocytes began to show signs of becoming reactive. They activated specific internal signaling pathways that are known to drive inflammation and started producing more of a protein called GFAP, which is a standard marker for an activated astrocyte. The researchers also found that the astrocytes were expressing a receptor called Transgelin-2, suggesting this might be the specific handle the soluble protein uses to grab onto the astrocyte and send its signal.
Once the astrocytes were activated by the soluble TREM2, the barrier itself began to fail. The researchers measured the permeability of their model by adding a fluorescent dye to the top of the dish and seeing how much leaked through to the bottom. They found that when the astrocytes were exposed to the protein, the barrier became significantly more leaky, allowing the dye to pass through much more easily than in untreated controls. This leakage was not random; it was linked to a breakdown in the tight seals between the blood vessel cells. Specifically, the levels of a key sealing protein called Occludin dropped significantly in the blood vessel cells. The researchers observed that the remaining Occludin was being broken down into smaller fragments, indicating that something was actively dismantling the barrier's structure.
The study identified the culprit behind this dismantling. The activated astrocytes began releasing a specific enzyme called Matrix Metalloproteinase-2, or MMP2. This enzyme is known to chew up structural proteins. The researchers found that the amount of MMP2 released by the astrocytes increased substantially after they were exposed to soluble TREM2. This suggests a clear chain of events: the soluble protein triggers the astrocytes, which in turn release MMP2, and this enzyme degrades the Occludin seals, causing the barrier to become permeable. While the team also looked for other inflammatory signals, such as various cytokines, they did not find strong statistical evidence that these other molecules were the primary drivers in this specific process, though some showed a slight upward trend.
This work provides a direct link between a protein associated with neurocognitive disorders and the physical breakdown of the blood-brain barrier. It demonstrates that soluble TREM2 is not just a bystander in disease but an active agent that can alter the behavior of astrocytes to compromise the brain's defenses. By pinpointing MMP2 as the tool used to break the barrier, the study highlights a potential target for future therapies. If scientists can block this enzyme or prevent the astrocytes from releasing it, they might be able to preserve the integrity of the blood-brain barrier in patients suffering from conditions where this protection is lost. The findings offer a clearer picture of how molecular changes in the brain's immune environment can lead to structural failure, opening new avenues for understanding and treating neurological diseases.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.